Roth Capital Expects Higher Earnings for Moleculin Biotech

Moleculin Biotech, Inc. (NASDAQ:MBRX) – Analysts at Roth Capital lifted their Q1 2025 earnings estimates for shares of Moleculin Biotech in a research report issued on Monday, March 24th. Roth Capital analyst J. Aschoff now expects that the company will post earnings of ($0.71) per share for the quarter, up from their prior forecast of ($1.26). The consensus estimate for Moleculin Biotech’s current full-year earnings is ($7.98) per share. Roth Capital also issued estimates for Moleculin Biotech’s Q2 2025 earnings at ($0.46) EPS, Q3 2025 earnings at ($0.46) EPS, Q4 2025 earnings at ($0.46) EPS, FY2025 earnings at ($2.02) EPS, FY2026 earnings at ($1.80) EPS, FY2027 earnings at ($1.73) EPS, FY2028 earnings at ($1.66) EPS and FY2029 earnings at $1.69 EPS.

Several other brokerages have also issued reports on MBRX. HC Wainwright reaffirmed a “buy” rating and set a $8.00 target price on shares of Moleculin Biotech in a research report on Monday. Maxim Group raised Moleculin Biotech from a “hold” rating to a “buy” rating and set a $4.00 price objective on the stock in a research note on Tuesday. Finally, StockNews.com upgraded shares of Moleculin Biotech to a “sell” rating in a research report on Wednesday.

Moleculin Biotech Trading Down 7.0 %

Shares of NASDAQ:MBRX opened at $1.07 on Wednesday. Moleculin Biotech has a 52 week low of $0.40 and a 52 week high of $6.23. The firm’s fifty day moving average is $1.32 and its 200-day moving average is $1.99.

About Moleculin Biotech

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.